Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arun A Azad

Showing results (91-100 of 140) with videos related to

Pageof 14
Sort By:
Clinical Genitourinary Cancer|May 4, 2025
Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry studyColin Williams, Andrisha-Jade Inderjeeth, Wei Hong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2026
Prognostic Value of Restaging [<sup>18</sup>F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 TherapyRaghava Kashyap, James P Buteau, Nathan Papa, et al.
Cancer Discovery|January 26, 2018
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerMatti Annala, Gillian Vandekerkhove, Daniel Khalaf, et al.
European Urology|May 13, 2023
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHESAndrew J Armstrong, Taro Iguchi, Arun A Azad, et al.
The New England Journal of Medicine|June 1, 2026
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate CancerNeeraj Agarwal, Nobuaki Matsubara, Arun A Azad, et al.
Prostate Cancer and Prostatic Diseases|March 22, 2021
Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancerHui-Ming Lin, Kevin Huynh, Manish Kohli, et al.
European Urology Oncology|August 8, 2020
Phase I/II Trial of the Combination of <sup>177</sup>Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)Megan Crumbaker, Sarennya Pathmanandavel, Andrew O Yam, et al.
JAMA Network Open|May 7, 2025
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical TrialArun A Azad, Daniel P Petrylak, Taro Iguchi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL StudyCristian Udovicich, Mathias Bressel, Jamil Manji, et al.
The Lancet. Oncology|October 19, 2022
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trialJames P Buteau, Andrew J Martin, Louise Emmett, et al.
Pageof 14

Showing results (91-100 of 140) with videos related to

Sort By:
Pageof 14
Clinical Genitourinary Cancer|May 4, 2025
Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry studyColin Williams, Andrisha-Jade Inderjeeth, Wei Hong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2026
Prognostic Value of Restaging [<sup>18</sup>F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 TherapyRaghava Kashyap, James P Buteau, Nathan Papa, et al.
Cancer Discovery|January 26, 2018
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerMatti Annala, Gillian Vandekerkhove, Daniel Khalaf, et al.
European Urology|May 13, 2023
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHESAndrew J Armstrong, Taro Iguchi, Arun A Azad, et al.
The New England Journal of Medicine|June 1, 2026
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate CancerNeeraj Agarwal, Nobuaki Matsubara, Arun A Azad, et al.
Prostate Cancer and Prostatic Diseases|March 22, 2021
Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancerHui-Ming Lin, Kevin Huynh, Manish Kohli, et al.
European Urology Oncology|August 8, 2020
Phase I/II Trial of the Combination of <sup>177</sup>Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)Megan Crumbaker, Sarennya Pathmanandavel, Andrew O Yam, et al.
JAMA Network Open|May 7, 2025
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical TrialArun A Azad, Daniel P Petrylak, Taro Iguchi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL StudyCristian Udovicich, Mathias Bressel, Jamil Manji, et al.
The Lancet. Oncology|October 19, 2022
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trialJames P Buteau, Andrew J Martin, Louise Emmett, et al.
Pageof 14